Kodiak Sciences Inc. - 8-K Filing
Kodiak Sciences reported Q1 2026 financial results with a net loss of $58.2 million, or $0.94 per share, compared to $57.5 million, or $1.09 per share, in Q1 2025. The company ended the quarter with $169.5 million in cash and cash equivalents, which is expected to fund operations through 2027. R&D expenses increased to $48.5 million due to clinical activities for the PEAK/PINNACLE and DAYBREAK studies. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $KOD